Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.